Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases

  title={Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases},
  author={L. Jordheim and D. Durantel and F. Zoulim and C. Dumontet},
  journal={Nature Reviews Drug Discovery},
  • L. Jordheim, D. Durantel, +1 author C. Dumontet
  • Published 2013
  • Biology, Medicine
  • Nature Reviews Drug Discovery
  • Nucleoside analogues have been in clinical use for almost 50 years and have become cornerstones of treatment for patients with cancer or viral infections. The approval of several additional drugs over the past decade demonstrates that this family still possesses strong potential. Here, we review new nucleoside analogues and associated compounds that are currently in preclinical or clinical development for the treatment of cancer and viral infections, and that aim to provide increased response… CONTINUE READING
    588 Citations

    Figures, Tables, and Topics from this paper

    Explore Further: Topics Discussed in This Paper

    Selected nucleos(t)ide-based prescribed drugs and their multi-target activity
    • 7
    • Highly Influenced
    The search for nucleoside/nucleotide analog inhibitors of dengue virus.
    • 43
    Advancement in the development of heterocyclic nucleosides for the treatment of cancer - A review
    • 6
    Nucleoside analogs and tuberculosis: new weapons against an old enemy.
    • 11
    • PDF
    Antiviral Nucleoside and Nucleotide Analogs: A Review
    • 7
    • PDF


    Progress in the development of new therapies for herpesvirus infections.
    • 45
    Review of recent studies on resistance to cytotoxic deoxynucleoside analogues.
    • 84
    Acyclic nucleoside phosphonates: a key class of antiviral drugs
    • 518
    HIV chemotherapy
    • 232
    Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus.
    • 63
    • PDF
    HIV chemotherapy : AIDS
    • 265
    Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine.
    • 20
    • PDF
    A novel anticancer agent ARC antagonizes HIV-1 and HCV
    • 17
    • PDF